Alnylam Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated: A Comprehensive Revenue Analysis

Biotech Revenue Trends: Alnylam vs. Ligand

__timestampAlnylam Pharmaceuticals, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 20145056100064538000
Thursday, January 1, 20154109700071914000
Friday, January 1, 201647159000108973000
Sunday, January 1, 201789912000141102000
Monday, January 1, 201874908000251453000
Tuesday, January 1, 2019219750000120282000
Wednesday, January 1, 2020492853000186419000
Friday, January 1, 2021844287000277133000
Saturday, January 1, 20221037418000196245000
Sunday, January 1, 20231828292000131314000
Monday, January 1, 20242248243000
Loading chart...

Unleashing the power of data

A Tale of Two Biotechs: Alnylam vs. Ligand

In the ever-evolving world of biotechnology, Alnylam Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated have carved distinct paths over the past decade. From 2014 to 2023, Alnylam's revenue skyrocketed by an astounding 3,500%, reaching its peak in 2023. This growth reflects the company's innovative strides in RNA interference therapeutics. In contrast, Ligand Pharmaceuticals experienced a more modest revenue increase of approximately 100% over the same period, peaking in 2021. This divergence highlights the varied strategies and market responses within the biotech sector.

Key Insights

  • Alnylam's Surge: Alnylam's revenue growth, particularly from 2020 onwards, underscores its successful product launches and market expansion.
  • Ligand's Stability: Despite slower growth, Ligand's consistent revenue reflects its steady licensing and royalty-based business model.

This analysis offers a glimpse into the dynamic landscape of biotech revenues, showcasing the potential for both explosive growth and steady performance.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025